Nanoformulations of albendazole as effective anticancer and antiparasite agents.

Initially emerging as a widely used clinical antiparasitic drug, albendazole (ABZ) has been increasingly recognized as an effective anticancer agent due to its outstanding advantage, in other words, low toxicity to normal cells but high effectiveness against parasites and some tumors. The major challenge is its poor water solubility and subsequently low bioavailability. This article thus first reviews the brief achievements in using ABZ to treat parasites and cancers, and summarizes the basic mechanisms of action of ABZ. Then this article critically reviews recent nanotechnological strategies, in other words, formulating/conjugating it with carriers into nanoformulations, in practices of improving aqueous solubility and efficacy in treatment of tumors and parasites. Our expert opinions in this field are provided for more effective delivery of ABZ to treat tumors and parasites in vivo.

[1]  U. Shinde,et al.  Solid Lipid Nanoparticles of Albendazole for Treatment of Toxocara Canis Infection: In-Vivo Efficacy Studies , 2017 .

[2]  Jin-Ki Kim,et al.  Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles. , 2017, Carbohydrate polymers.

[3]  Wenjun Zhang,et al.  Diamond nanostructures for drug delivery, bioimaging, and biosensing. , 2017, Chemical Society reviews.

[4]  E. B. Parisotto,et al.  Albendazole as a promising molecule for tumor control , 2016, Redox biology.

[5]  Irshad Ahmad,et al.  Copper(II) oxide nanoparticles augment antifilarial activity of Albendazole: In vitro synergistic apoptotic impact against filarial parasite Setaria cervi. , 2016, International journal of pharmaceutics.

[6]  S. Samanta,et al.  Acyclic Cucurbit[n]uril-Type Molecular Container Enables Systemic Delivery of Effective Doses of Albendazole for Treatment of SK-OV-3 Xenograft Tumors. , 2016, Molecular pharmaceutics.

[7]  Tao Song,et al.  Comparative Evaluation of Liposomal Albendazole and Tablet-Albendazole Against Hepatic Cystic Echinococcosis , 2016, Medicine.

[8]  M. Fatiha,et al.  Density functional study of inclusion complex of Albendazole/cucurbit [7]uril: Structure, electronic properties, NBO, GIAO and TD-DFT analysis , 2015 .

[9]  M. Ibrahim,et al.  Synthesis, characterization and medical efficacy (hepatoprotective and antioxidative) of albendazole-based copper(II) complexes – an experimental and theoretical approach , 2015 .

[10]  H. Valizadeh,et al.  Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. , 2015, Advanced pharmaceutical bulletin.

[11]  E. Saavedra,et al.  Albendazole induces oxidative stress and DNA damage in the parasitic protozoan Giardia duodenalis , 2015, Front. Microbiol..

[12]  Roger Liang,et al.  Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model , 2015, Journal of Nanobiotechnology.

[13]  Mengjiao Zhou,et al.  Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis. , 2015, Nanoscale.

[14]  Jin-Ki Kim,et al.  Exploring the Preparation of Albendazole-Loaded Chitosan-Tripolyphosphate Nanoparticles , 2015, Materials.

[15]  Jeong-Sook Park,et al.  Determination of preparation parameters for albendazole-loaded nanoparticles using chitosan and tripolyphosphate , 2015, Journal of Pharmaceutical Investigation.

[16]  Chun‐Sing Lee,et al.  Preparation and size control of sub-100 nm pure nanodrugs. , 2015, Nano letters.

[17]  G. Riggins,et al.  Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. , 2015, Antioxidants & redox signaling.

[18]  H. Y. Darani,et al.  Mutual action of anticancer and antiparasitic drugs: are there any shared targets? , 2014, Future oncology.

[19]  D. Morris,et al.  Albendazole loaded albumin nanoparticles for ovarian cancer therapy , 2014 .

[20]  Q. Xiong,et al.  Bovine serum albumin nanoparticles as controlled release carrier for local drug delivery to the inner ear , 2014, Nanoscale Research Letters.

[21]  Jaya Lakkakula,et al.  A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications. , 2014, Nanomedicine.

[22]  C. Hempel,et al.  Effects of the vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor SU5416 on in vitro cultures of Plasmodium falciparum , 2014, Malaria Journal.

[23]  M. Lamas,et al.  Modified β-Cyclodextrin Inclusion Complex to Improve the Physicochemical Properties of Albendazole. Complete In Vitro Evaluation and Characterization , 2014, PloS one.

[24]  P. Choyke,et al.  Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? , 2013, Theranostics.

[25]  A. Oryan,et al.  In vivo evaluation of the efficacy of albendazole sulfoxide and albendazole sulfoxide loaded solid lipid nanoparticles against hydatid cyst. , 2013, Experimental parasitology.

[26]  L. Skálová,et al.  Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines , 2013, Anti-cancer drugs.

[27]  Wei-xin Ren,et al.  Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats. , 2013, Journal of biomedical materials research. Part B, Applied biomaterials.

[28]  D. Morris,et al.  Combination of Albendazole and 2-Methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice , 2013, BMC Cancer.

[29]  Xiaowei Ma,et al.  Metallofullerol nanoparticles with low toxicity inhibit tumor growth by induction of G0/G1 arrest. , 2013, Nanomedicine.

[30]  Thomas C. Chen,et al.  Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. , 2012, Cancer letters.

[31]  M. Stenzel,et al.  Shell cross-linking of cyclodextrin-based micelles via supramolecular chemistry for the delivery of drugs. , 2012, Macromolecular rapid communications.

[32]  D. Morris,et al.  Complexation of albendazole with hydroxypropyl-β-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice. , 2012, Anticancer research.

[33]  T. Miner,et al.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. , 2012, World journal of gastrointestinal surgery.

[34]  Ahmed O Elzoghby,et al.  Albumin-based nanoparticles as potential controlled release drug delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[35]  N. Doudican,et al.  Albendazole sensitizes cancer cells to ionizing radiation , 2011, Radiation oncology.

[36]  Jun Li,et al.  Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. , 2011, Biomaterials.

[37]  A. Wright,et al.  A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis , 2011, Investigational New Drugs.

[38]  A. Tanoğlu,et al.  An Extremely Uncommon Case of Parasitic Infection Presenting as Eosinophilic Ascites in a Young Patient , 2011, Case Reports in Gastroenterology.

[39]  E. Choi,et al.  Differential Effect of Intraperitoneal Albendazole and Paclitaxel on Ascites Formation and Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cell-Bearing Athymic Nude Mice , 2011, Reproductive Sciences.

[40]  A. Olivieri,et al.  In vivo evaluation of albendazole microspheres for the treatment of Toxocara canis larva migrans. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[41]  Lisa Wang,et al.  Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. , 2010, Biochemical and biophysical research communications.

[42]  H. Esumi,et al.  The NADH‐fumarate reductase system, a novel mitochondrial energy metabolism, is a new target for anticancer therapy in tumor microenvironments , 2010, Annals of the New York Academy of Sciences.

[43]  Aiqin Wang,et al.  A novel pH-sensitive magnetic alginate–chitosan beads for albendazole delivery , 2010, Drug development and industrial pharmacy.

[44]  Jonathan Y. Mane,et al.  Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives , 2010, Molecular Cancer.

[45]  M. Poruchynsky,et al.  Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole , 2010, BMC Cancer.

[46]  A. Hoerauf,et al.  Filariasis and lymphoedema , 2009, Parasite immunology.

[47]  S. Badar,et al.  Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. , 2009, Anticancer research.

[48]  C. Salomon,et al.  High efficacy of albendazole-PEG 6000 in the treatment of Toxocara canis larva migrans infection. , 2009, The Journal of antimicrobial chemotherapy.

[49]  N. Parry,et al.  Presumptive albendazole toxicosis in 12 alpacas. , 2009, Journal of veterinary internal medicine.

[50]  J. Collins,et al.  Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit[n]uril. , 2008, Organic & biomolecular chemistry.

[51]  D. Morris,et al.  Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells. , 2008, Anticancer research.

[52]  Zhirong Zhang,et al.  Preparation and Evaluation of Poly-Butylcyanoacrylate Nanoparticles for Oral Delivery of Thymopentin , 2008, Journal of Pharmaceutical Sciences.

[53]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[54]  Barnes Kitsao,et al.  High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria , 2008, Proceedings of the National Academy of Sciences.

[55]  Zhang Qiang,et al.  Studies on the Drug-Loading Mechanism of Polybutylcyanocrylate Nanoparticle and its Stability of Thermodynamics , 2008 .

[56]  D. Morris,et al.  Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. , 2007, Biochemical pharmacology.

[57]  K. Sawanyawisuth,et al.  Albendazole therapy for eosinophilic meningitis caused by Angiostrongylus cantonensis , 2007, Parasitology Research.

[58]  I. Moreira,et al.  Vascular endothelial growth factor (VEGF) inhibition--a critical review. , 2007, Anti-cancer agents in medicinal chemistry.

[59]  V. V. van Hinsbergh,et al.  Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton , 2006, Molecular Cancer Therapeutics.

[60]  R. Manavalan,et al.  Studies on mechanism of enhanced dissolution of albendazole solid dispersions with crystalline carriers , 2006 .

[61]  Hirohisa Yano,et al.  Angiogenesis in Cancer , 2006, Vascular health and risk management.

[62]  Qiang Zhang,et al.  Alternative Albendazole Polybutylcyanoacrylate Nanoparticles Preparation, Pharmaceutical Properties and Tissue Distribution in Rats , 2006 .

[63]  D. Morris,et al.  Albendazole inhibits paclitaxel-resistant 1A9PTX22 ovarian cancer cells. , 2006 .

[64]  Lisa I. Wang,et al.  Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice , 2006, Clinical Cancer Research.

[65]  V. Heussler,et al.  The use of anticancer drugs in antiparasitic chemotherapy. , 2006, Mini reviews in medicinal chemistry.

[66]  R. Badea,et al.  Eosinophilic ascites in a patient with toxocara canis infection. A case report. , 2005, Romanian journal of gastroenterology.

[67]  G. Yagci,et al.  Results of Surgical, Laparoscopic, and Percutaneous Treatment for Hydatid Disease of the Liver: 10 Years Experience with 355 Patients , 2005, World Journal of Surgery.

[68]  C. Ehrhardt,et al.  Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[69]  Lisa I. Wang,et al.  Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis , 2005, Cancer Chemotherapy and Pharmacology.

[70]  C. Plowe,et al.  Mechanisms of Resistance of Malaria Parasites to Antifolates , 2005, Pharmacological Reviews.

[71]  K. Plate,et al.  Inhibition of solid tumor growth by gene transfer of VEGF receptor‐1 mutants , 2004, International journal of cancer.

[72]  S. Lai,et al.  The efficacy of therapy with albendazole in mice with parasitic meningitis caused by Angiostrongylus cantonensis , 2004, Parasitology Research.

[73]  P. Kremsner,et al.  Angiogenic proteins in brains of patients who died with cerebral malaria , 2003, Journal of Neuroimmunology.

[74]  Qiang Zhang,et al.  [Preparation of albendazole polybutycyanocrylate nanoparticles and study on its pharmaceutical properties and tissue distribution]. , 2003, Yao xue xue bao = Acta pharmaceutica Sinica.

[75]  G. Jayson,et al.  The current and future management of malignant ascites. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[76]  J. Horton.  Albendazole for the treatment of echinococcosis. , 2003, Fundamental & clinical pharmacology.

[77]  J. Torrado,et al.  Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole. , 2003, International journal of pharmaceutics.

[78]  P. Chiap,et al.  Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[79]  H. El-Abhar,et al.  The effect of Nigella sativa oil against the liver damage induced by Schistosoma mansoni infection in mice. , 2002, Journal of ethnopharmacology.

[80]  D. Morris,et al.  Pilot Study of Albendazole in Patients with Advanced Malignancy , 2001, Oncology.

[81]  Ming Chen,et al.  Inhibition of Fumarate Reductase inLeishmania major and L. donovani by Chalcones , 2001, Antimicrobial Agents and Chemotherapy.

[82]  D. Morris,et al.  In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. , 2001, Cancer letters.

[83]  F. Gilbert,et al.  Efficacy of albendazole against Giardia and hookworm in a remote Aboriginal community in the north of Western Australia. , 1998, Acta tropica.

[84]  R. Moreno-Esparza,et al.  Biopharmaceutics: Absorption Studies of Albendazole and Some Physicochemical Properties of the Drug and Its Metabolite Albendazole Sulphoxide , 1998, The Journal of pharmacy and pharmacology.

[85]  R. Gilman,et al.  Albendazole therapy for neurocysticercosis , 1997, Neurology.

[86]  R. J. Horton.  Albendazole in treatment of human cystic echinococcosis: 12 years of experience. , 1997, Acta tropica.

[87]  R. New,et al.  Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administratration with cimetidine , 1996, Parasitology.

[88]  P. Pitisuttithum,et al.  A randomized comparative study of albendazole and thiabendazole in chronic strongyloidiasis. , 1995, The Southeast Asian journal of tropical medicine and public health.

[89]  F. Carrasco,et al.  Neurocysticercosis: optimal dose treatment with albendazole , 1995, Journal of the Neurological Sciences.

[90]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[91]  R. Dal-Ré,et al.  Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease , 1993, The Lancet.

[92]  N. Beeching,et al.  Albendazole is effective treatment for chronic strongyloidiasis. , 1993, The Quarterly journal of medicine.

[93]  O. Takayanagui,et al.  Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. , 1992, Archives of neurology.

[94]  E. Lacey.  The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. , 1988, International journal for parasitology.

[95]  D. Morris.  Pre‐operative albendazole therapy for hydatid cyst , 1987, The British journal of surgery.

[96]  F. Ashall.  Cancer cells and parasites: two of a kind , 1986 .

[97]  E. Lacey,et al.  Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay. , 1985, Biochemical pharmacology.

[98]  M. Barrowman,et al.  The binding and subsequent inhibition of tubulin polymerization in Ascaris suum (in vitro) by benzimidazole anthelmintics. , 1984, Biochemical pharmacology.

[99]  A. Crémieux,et al.  ALBENDAZOLE AS A POTENTIAL TREATMENT FOR HUMAN HYDATIDOSIS , 1983, The Lancet.

[100]  A. Khaleel,et al.  Host–guest complexes of cucurbit[7]uril with albendazole in solid state , 2012, Journal of Thermal Analysis and Calorimetry.

[101]  K. Cottingham.  A new PTM for tubulin is found in a parasite. , 2010, Journal of proteome research.

[102]  T. Furuta,et al.  Elevated levels of vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor (VEGFR)-2 in human malaria. , 2010, The American journal of tropical medicine and hygiene.

[103]  S. Tzipori,et al.  Analysis of the β‐Tubulin Genes from Enterocytozoon bieneusi Isolates from a Human and Rhesus Macaque , 2007, The Journal of eukaryotic microbiology.

[104]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[105]  Ruiwen Zhang,et al.  Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I , 1998, Cancer Chemotherapy and Pharmacology.

[106]  É. Oksenhendler,et al.  Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. , 1995, The Journal of infectious diseases.

[107]  D. Dieterich,et al.  Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. , 1994, The Journal of infectious diseases.

[108]  R. J. Horton.  Chemotherapy of Echinococcus infection in man with albendazole. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[109]  K. Vutova,et al.  Albendazole treatment of multiple cerebral hydatid cysts: case report. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[110]  H. Maisonneuve,et al.  Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis. , 1983, Transactions of the Royal Society of Tropical Medicine and Hygiene.